Clinical trials: Dendritic Cell
Melanoma Stage III or IV
Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Dendritic cells (DCs)are the most potent antigen-presenting cells of the immune system, as such they are able to direct the immune system specifically against cancer cells.
- Trial name
- NCT00243529
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Radboud University Medical Center
Pancreatic Cancer
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.
- Trial name
- NCT01781520
- Testing
- DC-CIK Treatment, S1, Best supportive care
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Capital Medical University
Breast Cancer
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
The primary goals of this trial will be to determine the safety and immune activity of HER-2 pulsed DC1 vaccine in patients with high risk HER-2pos breast cancer with residual disease post neoadjuvant therapy.
- Trial name
- Neoadjuvant (NCT02061423)
- Testing
- HER-2 pulsed Dendritic Cell Vaccine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Melanoma Patients Immunized with Natural DenDritic Cells
The aim of this study is to determine whether adjuvant treatment with nDC vaccination, after complete radical lymph node dissection or sentinel node procedure in stage IIIB and IIIC melanoma patients, improves recurrence-free…
- Trial name
- MIND-DC (NCT02993315)
- Testing
- nDC vaccination
- Where
- 5 sites in Netherlands
- Volunteers
- 148 people
- Sponsor
- Radboud University Medical Center
Glioblastoma
Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
The primary objective of the study is to determine whether overall survival of newly diagnosed glioblastoma patients treated with lysate-loaded, mature dendritic cell vaccines as add-on to the standard of care consisting of…
- Trial name
- GlioVax (NCT03395587)
- Testing
- Autologous, tumor lysate-loaded, mature dendritic cells (DC), standard therapy
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Epithelial Ovarian Cancer
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
In this study the investigators will include patients with relapsed epithelial ovarian cancer. In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and…
- Trial name
- NCT01334047
- Testing
- DC-006 vaccine
- Where
- Norway
- Volunteers
- 5 people
- Sponsor
- Steinar Aamdal
Hematologic Malignancy
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
The purpose of this study is to test the safety of adding donor dendritic cells to donor lymphocyte infusions, and to determine the type and severity of any side effects associated with this addition.
- Trial name
- NCT00476177
- Testing
- Infusion of donor dendritic cells, Infusion of donor lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
This phase I trial is studying the side effects and best dose of bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma or anaplastic…
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00458731
- Testing
- bevacizumab, cediranib maleate
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00068302
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Philadelphia
HIV Infections
Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection
Phase I test of concept study: In an attempt to induce new immunity to HIV-1 during untreated HIV-1 infection the investigators have identified relatively immune silent immune subdominant HLA-A2-restricted HIV-1 CTL epitopes that…
- Trial name
- HIVDCVac (NCT00856154)
- Testing
- Peptides on autologous Dendritic Cells
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Statens Serum Institut
Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
The aim of this clinical trial is to evaluate the efficacy and safety of consolidation therapy with a neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) following radical chemoradiotherapy or chemoradiation-immunotherapy in…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06675201
- Testing
- neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Sichuan University
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery…
- Trial name
- NCT06152367
- Testing
- TAPCells vaccine
- Where
- Chile
- Volunteers
- 90 people
- Sponsor
- University of Chile
Large Cell Lymphoma
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
- Trial name
- NCT00099255
- Testing
- SGN-30
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Seagen Inc.
Lymphoma, Solid Tumor
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
RATIONALE: Studying the dendritic cells in samples of blood from patients with cancer receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic cells.
- Trial name
- NCT00896662
- Testing
- immunologic technique, laboratory biomarker analysis, pharmacological study
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Myeloid Leukemia, Chronic
DC Vaccination in CML
The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells.
- Trial name
- NCT02543749
- Testing
- DC vaccine
- Where
- 2 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Charite University, Berlin, Germany
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003716
- Testing
- rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
DLBCL - Diffuse Large B Cell Lymphoma
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
This is an open-label, multicentre, randomized phase II non-inferiority trial aiming to compare the efficacy and safety of 4 versus 6 cycles of CHP (administered at 21-day intervals), both in combination with 6 cycles of…
- Trial name
- NCT07034508
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China